Sökning: WFRF:(Goede A.) > (2020-2023) > First-Line Venetocl...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08634naa a2201777 4500 | |
001 | oai:lup.lub.lu.se:42fbc9a8-25f1-4568-8e98-7281f9b05f0f | |
003 | SwePub | |
008 | 231113s2023 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:liu-196901 | |
024 | 7 | a https://lup.lub.lu.se/record/42fbc9a8-25f1-4568-8e98-7281f9b05f0f2 URI |
024 | 7 | a https://doi.org/10.1056/NEJMoa22130932 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1969012 URI |
040 | a (SwePub)lud (SwePub)liu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Eichhorst, B.u University Hospital of Cologne,Univ Cologne, Germany4 aut |
245 | 1 0 | a First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. |
264 | 1 | b MASSACHUSETTS MEDICAL SOC,c 2023 |
300 | a 16 s. | |
500 | a Funding Agencies|AbbVie | |
520 | a Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. Methods In a phase 3, open-label trial, we randomly assigned, in a 1:1:1:1 ratio, fit patients with CLL who did not have TP53 aberrations to receive six cycles of chemoimmunotherapy (fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab) or 12 cycles of venetoclax-rituximab, venetoclax-obinutuzumab, or venetoclax-obinutuzumab-ibrutinib. Ibrutinib was discontinued after two consecutive measurements of undetectable minimal residual disease or could be extended. The primary end points were undetectable minimal residual disease (sensitivity, | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng |
653 | a Hematology/Oncology | |
653 | a Leukemia/Lymphoma | |
653 | a Treatments in Oncology | |
653 | a bendamustine | |
653 | a cyclophosphamide | |
653 | a fludarabine | |
653 | a ibrutinib | |
653 | a obinutuzumab | |
653 | a rituximab | |
653 | a venetoclax | |
653 | a aged | |
653 | a alanine aminotransferase level | |
653 | a anemia | |
653 | a Article | |
653 | a atrial fibrillation | |
653 | a blood | |
653 | a breast disease | |
653 | a cancer combination chemotherapy | |
653 | a chronic lymphatic leukemia | |
653 | a connective tissue disease | |
653 | a controlled study | |
653 | a death | |
653 | a diarrhea | |
653 | a disease exacerbation | |
653 | a drug efficacy | |
653 | a drug safety | |
653 | a drug withdrawal | |
653 | a faintness | |
653 | a febrile neutropenia | |
653 | a female | |
653 | a fever | |
653 | a first-line treatment | |
653 | a flow cytometry | |
653 | a genital system disease | |
653 | a human | |
653 | a human cell | |
653 | a hypersensitivity | |
653 | a hypertension | |
653 | a hypophosphatemia | |
653 | a infection | |
653 | a influenza | |
653 | a leukocyte | |
653 | a leukocyte count | |
653 | a leukopenia | |
653 | a major clinical study | |
653 | a male | |
653 | a minimal residual disease | |
653 | a multiple cycle treatment | |
653 | a musculoskeletal disease | |
653 | a neutropenia | |
653 | a neutrophil count | |
653 | a non melanoma skin cancer | |
653 | a open study | |
653 | a phase 3 clinical trial | |
653 | a platelet count | |
653 | a pneumonia | |
653 | a postoperative complication | |
653 | a progression free survival | |
653 | a prospective study | |
653 | a randomized controlled trial | |
653 | a side effect | |
653 | a skin disease | |
653 | a solid tumor | |
653 | a thrombocytopenia | |
653 | a treatment response | |
653 | a tumor lysis syndrome | |
653 | a upper respiratory tract infection | |
653 | a urinary tract infection | |
700 | 1 | a Juliusson, Gunnaru Lund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Leukemi, genetik, epidemiologi,Forskargrupper vid Lunds universitet,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Leukemia, Genetics, Epidemiology,Lund University Research Groups,Lund Univ, Sweden4 aut0 (Swepub:lu)stem-gju |
700 | 1 | a Hallek, Mu University Hospital of Cologne,Univ Cologne, Germany4 aut |
700 | 1 | a Niemann, Carsten U.u Copenhagen Univ Hosp, Denmark4 aut |
700 | 1 | a Kater, Arnon P.u Univ Amsterdam, Netherlands4 aut |
700 | 1 | a Fuerstenau, Moritzu Univ Cologne, Germany4 aut |
700 | 1 | a von Tresckow, Juliau Univ Duisburg Essen, Germany4 aut |
700 | 1 | a Zhang, Canu Univ Cologne, Germany4 aut |
700 | 1 | a Robrecht, Sandrau Univ Cologne, Germany4 aut |
700 | 1 | a Gregor, Michaelu Luzerner Kantonsspital, Switzerland4 aut |
700 | 1 | a Thornton, Patricku Blackrock Hlth Member Hosp, Ireland4 aut |
700 | 1 | a Staber, Philipp B.u Med Univ Vienna, Austria4 aut |
700 | 1 | a Tadmor, Tamaru Bnai Zion Med Ctr, Israel4 aut |
700 | 1 | a Lindstrom, Vesau Helsinki Univ Hosp, Finland4 aut |
700 | 1 | a da Cunha-Bang, Casparu Copenhagen Univ Hosp, Denmark4 aut |
700 | 1 | a Schneider, Christofu Univ Ulm, Germany4 aut |
700 | 1 | a Poulsen, Christian B.u Zealand Univ Hosp, Denmark4 aut |
700 | 1 | a Illmer, Thomasu Grp Practice Hematol & Oncol, Germany4 aut |
700 | 1 | a Schoettker, Bjoernu Hematol Oncol Ctr, Germany4 aut |
700 | 1 | a Noesslinger, Thomasu Hanusch Hosp, Austria4 aut |
700 | 1 | a Janssens, Annu Univ Ziekenhuis Leuven, Belgium4 aut |
700 | 1 | a Christiansen, Ilseu Aalborg Univ Hosp, Denmark4 aut |
700 | 1 | a Baumann, Michaelu Kantonsspital St Gallen, Switzerland4 aut |
700 | 1 | a Frederiksen, Henriku Odense Univ Hosp, Denmark4 aut |
700 | 1 | a van der Klift, Marjoleinu Amphia Hosp, Netherlands4 aut |
700 | 1 | a Jaeger, Ulrichu Med Univ Vienna, Austria4 aut |
700 | 1 | a Leys, Maria B. L.u Maasstad Ziekenhuis, Netherlands4 aut |
700 | 1 | a Hoogendoorn, Melsu Med Ctr Leeuwarden, Netherlands4 aut |
700 | 1 | a Lotfi, Kouroshu Linköpings universitet,Avdelningen för klinisk kemi och farmakologi,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US4 aut0 (Swepub:liu)koulo97 |
700 | 1 | a Hebart, Holgeru Specialist Med Practice Hematol & Oncol, Germany4 aut |
700 | 1 | a Gaska, Tobiasu Bruderhosp St Josef, Germany4 aut |
700 | 1 | a Koene, Harryu St Antonius Hosp Utrecht, Netherlands4 aut |
700 | 1 | a Enggaard, Lisbethu Rigshosp, Denmark4 aut |
700 | 1 | a Goede, Jereonu Kantonsspital Hosp Winterthur, Switzerland4 aut |
700 | 1 | a Regelink, Josien C.u Meander Med Ctr, Netherlands4 aut |
700 | 1 | a Widmer, Anouku Univ Hosp Zurich, Switzerland4 aut |
700 | 1 | a Simon, Florianu Univ Cologne, Germany4 aut |
700 | 1 | a De Silva, Nishau UCL, England4 aut |
700 | 1 | a Fink, Anna-Mariau Univ Cologne, Germany4 aut |
700 | 1 | a Bahlo, Jasminu Univ Cologne, Germany4 aut |
700 | 1 | a Fischer, Kirstenu Univ Cologne, Germany4 aut |
700 | 1 | a Wendtner, Clemens-Martinu Ludwig Maximilians Univ Munchen, Germany4 aut |
700 | 1 | a Kreuzer, Karl A.u Univ Cologne, Germany4 aut |
700 | 1 | a Ritgen, Matthiasu Univ Hosp Schleswig Holstein, Germany4 aut |
700 | 1 | a Brueggemann, Monikau Univ Hosp Schleswig Holstein, Germany4 aut |
700 | 1 | a Tausch, Eugenu Univ Ulm, Germany4 aut |
700 | 1 | a Levin, Mark-Davidu Albert Schweitzer Hosp, Netherlands4 aut |
700 | 1 | a van Oers, Marinusu Univ Amsterdam, Netherlands4 aut |
700 | 1 | a Geisler, Christianu Copenhagen Univ Hosp, Denmark4 aut |
700 | 1 | a Stilgenbauer, Stephanu Univ Ulm, Germany4 aut |
710 | 2 | a University Hospital of Cologneb Univ Cologne, Germany4 org |
710 | 2 | a et al. |
773 | 0 | t New England Journal of Medicined : MASSACHUSETTS MEDICAL SOCg 388:19, s. 1739-1754q 388:19<1739-1754x 0028-4793x 1533-4406 |
856 | 4 | u http://dx.doi.org/10.1056/NEJMoa2213093y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/42fbc9a8-25f1-4568-8e98-7281f9b05f0f |
856 | 4 8 | u https://doi.org/10.1056/NEJMoa2213093 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-196901 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.